CASE DISCUSSION

Improving outcomes in IBD with early effective therapy & biosimilars

Presented from India by Dr. Salem Awadh

Likes

841114

Views

33,645

39,532

Bookmarks

Case Description

Improving outcomes in Inflammatory Bowel Disease (IBD) involves early and effective therapy to reduce inflammation and prevent complications. Utilizing biosimilars, which are cost-effective alternatives to biologic medications, can enhance treatment accessibility and adherence. Early intervention...

Case Summary

Sandos' pro-education grant supported a session on improving outcomes in Inflammatory Bowel Disease (IBD) with early, effective therapy and biosimilars. Sandos, a global leader in off-patent medicine, focuses on affordable medicines, biosimilars, and generics, aiming to reduce healthcare costs and improve access. Their portfolio includes about 1,500 biosimilars and generic medicines, contributing significantly to healthcare cost savings.

Speaker Profile

Dr. Salem Awadh

Consultant Gastroenterologist, Amrita Medical Center, Abu Dhabi

Dr. Salim Awad is a consultant gastroenterologist who has completed extensive training in Gastroenterology from India, Newcastle, Belgium, and France. He has worked in several prestigious hospitals, including Royal Victoria Infirmary in Newcastle, Al Jazira & Central Hospitals in the UAE, and Freeman Hospital. Dr. Salim has long experience in endoscopy management and liver disease with follow up for the patients with liver transplant. Dr. Awad provides teaching programs for undergraduates and junior doctors at Al Ain University and has attended prominent conferences such as the World Congress of Gastroenterology in Sydney, the Digestive Disease Conference in Amsterdam, and the New Advances in Gastroenterology Conference in Berlin.